Progress in randomized clinical trials of antifibrotic drug nintedanib and pirfenidone
10.3760/cma.j.issn.1001-9391.2020.01.016
- VernacularTitle: 抗肺纤维化药物尼达尼布和吡非尼酮临床试验进展
- Author:
Yihua LI
1
;
Qiao YE
Author Information
1. Department of Occupational Medicine and Toxicology, Clinical Center for Interstitial Lung Diseases, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China
- Publication Type:Review
- Keywords:
Pulmonary fibrosis;
Idiopathic pulmonary fibrosis;
Nintedanib;
Pirfenidone;
Clinical trials
- From:
Chinese Journal of Industrial Hygiene and Occupational Diseases
2020;38(1):62-65
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary fibrosis is the terminal manifestation of a variety of interstitial lung diseases. Idiopathic pulmonary fibrosis (IPF) is one of the chronic, progressive, fibrotic lung disease with high incidence and poor prognosis. Nintedanib and pirfenidone are currently marketed anti-pulmonary fibrosis drugs, and their efficacy and safety are recognized in patients with IPF. This article reviews the targets and clinical trials of the two drugs, and provides a basis for the expansion of indications for anti-pulmonary fibrosis drugs.
